Authors

Latest:

New Law Widens Access to Genetic Counseling but Licensure and Coverage Barriers Persist

Telehealth, a universal term for the use of digital information and communication technologies to remotely access healthcare services, is improving availability of healthcare services, particularly for patients in rural areas.

Heather Dalton, MD

Latest:

Dr. Dalton on Toxicities in the Frontline Treatment of Ovarian Cancer

Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses toxicities in the frontline treatment of patients with ovarian cancer.

Heather Greene, NP

Latest:

Toxicities Associated With VEGF TKIs and Checkpoint Inhibitors in mRCC

Heather Greene, a nurse practitioner at West Cancer Center, discusses the toxicities that are associated with VEGF TKIs and checkpoint inhibitors in metastatic renal cell carcinoma (mRCC).

Heather H. Cheng, MD, PhD

Latest:

Dr. Cheng on the Goals of the GENTleMEN Trial in Prostate Cancer

Heather H. Cheng, MD, PhD, discusses the goals of the ongoing GENTleMEN trial in prostate cancer.

Heather L. McArthur, MD, MPH, Cedars-Sinai Medical Center

Heather Leitch, MD, PhD, St. Paul’s Hospital

Heather S. Han, MD

Latest:

Dr. Han on the APHINITY Trial in HER2+ Early-Stage Breast Cancer

Heather S. Han, MD, discusses the benefit of adding pertuzumab to trastuzumab and chemotherapy in the phase 3 APHINITY trial in patients with HER2-positive early-stage breast cancer.

Heather S. Jim, PhD

Latest:

Dr. Jim on Real-World Quality of Life Outcomes With Axi-Cel in R/R LBCL

Heather Jim, PhD, discusses a real-world analysis, examining the quality of life outcomes seen with axicabtagene ciloleucel in patients with relapsed/refractory large B-cell lymphoma.

Heather Wakelee, MD

Latest:

Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

The panel discusses treatment considerations for consolidation durvalumab.

Heather Wakelee, MD, Stanford University

Latest:

Second-Line Treatment of SCLC

Vamsidhar Velcheti, MD, leads the discussion on the current standard of care and approaching the treatment of second-line SCLC.

Heather Yeo, MD, MHS

Latest:

There's an App for That: Keeping Patients and Physicians on Track

In a pilot study, funded by both the Society for Surgery of the Alimentary Tract and The Center for Advanced Digestive Care, researchers at Weill Cornell Medicine are testing a new mobile app that could help transform postoperative patient monitoring.

Heidi Donovan, PhD, RN

Latest:

Heidi Donovan Discusses Prioritizing Symptoms

Heidi Donovan from the University of Pittsburgh School of Nursing Discusses Prioritizing Symptoms

Heikki Joensuu, MD, PhD

Latest:

Dr. Joensuu Discusses Resistance to Imatinib in GIST

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST

Heiko Enderling, PhD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Heinz Gisslinger, MD

Latest:

Dr. Gisslinger on EFS Rates With Ropeginterferon Alfa-2b in Polycythemia Vera

Heinz Gisslinger, MD, discusses the 6-year event-free survival data from the phase 3 PROUD-PV and CONTI-PV trials.

Heinz-Josef Lenz, MD

Heinz-Josef Lenz, MD, is a professor of medicine and cancer biology, and the J. Terrence Lanni Chair in Gastrointestinal Cancer Research at the Keck School of Medicine of the University of the University of Southern California (USC); as well as the co-director of the USC Center for Molecular Pathway and Drug Discovery and the co-director of the USC Norris Center for Cancer Drug Development

Latest:

Dr Lenz on the FDA Approval of Nivolumab Plus Ipilimumab for dMMR/MSI-H mCRC

Heinz-Josef Lenz, MD, discusses data from the CheckMate 8HW trial that led to the FDA approval of nivolumab plus ipilimumab for dMMR/MSI-H metastatic CRC.

Heinz-Josef Lenz, MD, FACP, USC Norris Comprehensive Cancer Center

Latest:

Dr Lenz on the Prognostic Value of HER2 Expression in mCRC

Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.

Heinz-Josef Lenz, MD, FACP, USC Center for Molecular Pathway

Heinz-Josef Lenz, MD, USC

Latest:

Dr Lenz on the Association Between HER2 Expression and Treatment Outcomes in mCRC

Heinz-Josef Lenz, MD, FACP, discusses the association between HER2 expression and treatment outcomes in metastatic colorectal cancer.

Heinz Ludwig, MD, Wilhelminen Cancer Research Institute